CoChat

Amelioration of diabetes by imatinib mesylate (Gleevec®): role of ‐cell NF‐KB activation and anti‐apoptotic preconditioning

Hägerkvist, Robert, Sandler, Stellan, Mokhtari, Dariush, Welsh, Nils · 2007 · The FASEB Journal
Cited by 132

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

It was recently reported that tyrosine kinase inhibitor imatinib mesylate (Gleevec®) improves Type 2 diabetes, possibly by decreasing insulin resistance. However, as both Type 2 and Type 1 diabetes are characterized by β‐cell dysfunction and death, we investigated whether imatinib counteracts diabetes by maintaining β‐cell function. We observed that imatinib counteracted diabetes in two animal models, the streptozotocin‐injected mouse and the nonobese diabetes mouse, and that this was paralleled by a partial preservation of the β‐cell mass. In addition, imatinib decreased the death of human β‐cells in vitro when exposed to NO, cytokines, and streptozotocin. The imatinib effect was mimicked by siRNA‐mediated knockdown of c‐Abl mRNA. Imatinib enhanced β‐cell survival by promoting a state similar to ischemic preconditioning, as evidenced by NF‐B activation, increased NO and reactive oxygen species production, and depolarization of the inner mitochondrial membrane. Imatinib did not suppress islet cell death in the presence of an NF‐B inhibitor, suggesting that NF‐B activation is a necessary step in the antiapoptotic action of imatinib. We conclude that imatinib mediates β‐cell survival and that this could contribute to the beneficial effects observed in diabetes.—Hägerkvist, R., Sandler, S., Mokhtari, D., Welsh, N. Amelioration of diabetes by imatinib mesylate (Gleevec®): role of β‐cell NF‐B activation and anti‐apoptotic preconditioning. FASEB J. 21, 618–628 (2007)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fj.06-6910com

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 132

Metadata

Authors
Hägerkvist, R., Sandler, S., Mokhtari, D., & Welsh, N.
Venue
The FASEB Journal
Publisher
Wiley
Published
2006-11-29
Volume
21
Issue
2
Pages
618-628
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W1993124906
Cited by
132
References
4
FWCI
5.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amelioration of diabetes by imatinib mesylate (Gleevec®): role of ‐cell NF‐KB activation and anti‐apoptotic preconditioning. https://app.cochat.ai/papers/10.1096/fj.06-6910com
The paper
Hägerkvist, R., Sandler, S., Mokhtari, D., & Welsh, N. (2007). Amelioration of diabetes by imatinib mesylate (Gleevec®): role of ‐cell NF‐KB activation and anti‐apoptotic preconditioning. The FASEB Journal. https://doi.org/10.1096/fj.06-6910com

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.